DGAP-News: Oxford Immunotec /
Oxford Immunotec Announces Preliminary Fourth Quarter and Fiscal 2013
Revenue and Initiates 2014 Fiscal Year Guidance
13.01.2014 / 12:00
---------------------------------------------------------------------
-- Preliminary fourth quarter revenue of between $10.1 and $10.5 million, an
increase of 91% to 99% over the prior year
-- Preliminary 2013 revenue of between $38.6 and $39.0 million, an increase of
87% to 89% over 2012
-- 2014 Revenues expected to be in the range of $47 to $50 million
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 13, 2014 (GLOBE NEWSWIRE)
-- Ahead of its presentation at the JP Morgan Healthcare Conference in San
Francisco, Oxford Immunotec Global PLC (Nasdaq:OXFD) this morning announced
that based on preliminary unaudited financial data, the Company expects total
revenue for the fourth quarter of 2013 will be between $10.1 and $10.5 million.
For fiscal 2013, the Company expects total revenue of between $38.6 and $39.0
million. These preliminary results are subject to completion of the Company's
audit and other financial and accounting procedures.
'We are pleased with our revenues in the fourth quarter, which came in ahead of
our expectations despite the normal fourth quarter seasonality in our
business,' said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford
Immunotec. 'We are enthusiastic about the opportunities to continue to grow the
business in 2014.'
2014 Business Outlook
For the fiscal year ending December 31, 2014, Oxford Immunotec expects its full
year revenue to be in the range of $47 to $50 million.
Upcoming Webcasts & Conference Calls
Oxford Immunotec is scheduled to present on Thursday, January 16, 2014 at the
JP Morgan Healthcare Conference in San Francisco, CA at 12:30 PM Pacific Time.
A live webcast of the presentation will be available online from the investor
relations page of the Company's corporate website at www.oxfordimmunotec.com.
After the live webcast, the presentation will remain available on the website
for 90 days.
The Company will announce complete financial and operating results of its
fourth quarter and the full year ended December 31, 2013 prior to the market
opening on March 4, 2014. The Company will hold a conference call to discuss
the results that day at 8:00 AM Eastern Time.
NOTES TO EDITORS
About Oxford Immunotec Global PLC
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company
committed to improving patient care by providing advanced, innovative tests in
the field of immunology. The proprietary T-SPOT technology platform measures
the responses of specific immune cells, known as T cells, to inform the
diagnosis, prognosis and monitoring of patients with immunologically controlled
diseases. T cells are a central component of the human body's immune system,
and are implicated in the control and progression of many medical conditions,
including certain types of infectious diseases, cancers and autoimmune
diseases. The Company's lead product developed using the T-SPOT technology
platform is the T-SPOT.TB test, which is used to test for latent tuberculosis
infection. The T-SPOT.TB test has been approved for sale in over 50 countries,
including the United States, where it has received pre-market approval from the
Food and Drug Administration, in Europe, where it has obtained a CE mark, as
well as Japan and China. The Company is headquartered near Oxford, UK and in
Marlborough, MA.
Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
Forward-Looking Statements
This release contains forward-looking statements, including statements
regarding expectations relating to results based on preliminary, unaudited data
and future revenue. These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially. These risks
and uncertainties, includes, among others, our ability to successfully further
commercialize our T-SPOT.TB test, decisions by regulatory authorities, market
acceptance by hospitals and other health care institutions, laboratories,
physicians, patients and third party payers, continued demand for diagnostic
products for tuberculosis, and competition, as well as our ability to
expeditiously and successfully expand our sales and distribution networks and
the other factors described in the 'Risk Factors' section in our filings with
the Securities and Exchange Commission. The expectations regarding preliminary
financial data included in this release are also subject to completion of our
audit and other financial and accounting procedures, and the preliminary
results may differ from the actual results that we report following completion
of such procedures. When evaluating our business and securities, investors
should give careful consideration to these risks and uncertainties.
Forward-looking statements are based on current expectations and assumptions
and currently available data and are neither predictions nor guarantees of
future events or performance. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
presentation. We do not undertake to update or revise any forward-looking
statements after they are made, whether as a result of new information, future
events, or otherwise, except as required by applicable law.
CONTACTS:
For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley@oxfordimmunotec.com
For Investor Inquiries:
Rick Altieri
Chief Financial Officer,
Oxford Immunotec
Tel: +1 (508) 481-4648
raltieri@oxfordimmunotec.com
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500
oxfordimmunotec@westwicke.com
News Source: NASDAQ OMX
End of Corporate News
---------------------------------------------------------------------
13.01.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Oxford Immunotec
United Kingdom
ISIN: GB00BGFBB958
End of News DGAP News-Service
---------------------------------------------------------------------
247742 13.01.2014
DGAP-News: Oxford Immunotec Announces Preliminary Fourth Quarter and Fiscal 2013 Revenue and Initiates 2014 Fiscal Year Guidance
| Source: EQS Group AG